Emerging drugs for the treatment of tobacco dependence

Expert Opinion on Emerging Drugs

Volumn 14, Issue 1, 2009, Pages 23-32

  Ebbert, Jon O ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Nicotine replacement therapy (NRT); Nicotinic acetylcholine receptors (nAChRs)

Indexed keywords

AMFEBUTAMONE; CLONIDINE; CYTISINE; DIANICLINE; DIANICLINE PLUS RIMONABANT; NEUROTRANSMITTER; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NORTRIPTYLINE; PLACEBO; RIMONABANT; UNCLASSIFIED DRUG; VARENICLINE; BENZAZEPINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ABNORMAL DREAMING; AGITATION; APPLICATION SITE IRRITATION; BEHAVIOR; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CIGARETTE SMOKING; CLINICAL TRIAL; CONSTIPATION; COUGHING; DATA BASE; DEPRESSION; DIARRHEA; DISABILITY; DROWSINESS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG MIXTURE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HEARTBURN; HICCUP; HUMAN; HYPERTENSION; INDIGESTION; INSOMNIA; INTERNET; LOZENGE; MEDLINE; MORTALITY; MOUTH IRRITATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; REVIEW; REWARD; SEDATION; SIDE EFFECT; SMOKING CESSATION; SUBCAPSULAR CATARACT; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; THROAT IRRITATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; XEROSTOMIA; ANIMAL; DRUG EFFECT; METABOLISM; METHODOLOGY;

ANIMALS; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; HUMANS; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; RECEPTORS, NICOTINIC; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 65649111684     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210802623874     Document Type: Review

References (61)

1. World Health Organization. The facts about smoking and health, 2006 . Available from: http://www.wpro.who.int/media-centre/fact-sheets/fs-20060530.htm
2. World Health Organization. Smoking Statistics, 2002 . Available from: http://www.wpro.who.int/media-centre/fact-sheets/fs-20020528.htm • Global estimates of tobacco use.
3. US Department of Health and Human Services. The health consequences of smoking: Nicotine addiction. A report of the Surgeon General (Publication No. 88-8406). Washington, DC: US Government Printing Office; 1988
4. Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 1995;117(1):2-10; discussion 4-20
5. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13(5):177-184
6. Pontieri FE, Tanda G, Orzi F, et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382(6588):255-257 (Pubitemid 26251360)
7. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996;16(5):905-8 •• Review of the neurophysiology of nicotine dependence.
8. Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000;40:431-458 (Pubitemid 30340689)
9. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998;391(6663):173-7 • Key article in the discovery of the function of a 4 b 2 nAChRs. (Pubitemid 28092475)
10. Marubio LM, Gardier AM, Durier S, et al. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 2003;17(7):1329-37 • Key article in the discovery of the function of a 4 b 2 nAChRs.
11. American Cancer Society. Cancer Facts and Figures 2007. Available from: www.cancer.org
12. Annual smoking-attributable mortality, years of potential life lost, and economic costs: United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002;51(14):300-303
13. Center for Disease Control. Annual smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 1997-2001. Morb Mortal Wkly Rep 2005;54(25):625-8 • Magnitude of tobacco's adverse health effects.
14. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General, 1990. Publication No.(CDC) 90-8416. Washington, DC: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Office on Smoking and Health; 1990
15. Centers for Disease Control and Prevention. Cigarette smoking among adults: United States, 2006. MMWR Morb Mortal Wkly Rep 2007;56(44):1157-61 •• Current smoking prevalence in the United States.
16. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults- United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51(29):642-645
17. Fu SS, Partin MR, Snyder A, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? Am J Manag Care 2006;12(4):235-243
18. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2008 •• Extensive overview of all treatments for tobacco dependence.
19. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry 1993;11(1):2-14
20. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295(1):321-327 (Pubitemid 30746099)
21. Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004;66(3):675-682 (Pubitemid 39329267)
22. McCarthy DE, Piasecki TM, Lawrence DL, et al. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction 2008;103(9):1521-1533
23. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337(17):1195-1202 (Pubitemid 27454451)
24. Jorenby DE, Leischow SJ, Nides M, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9):685-691 (Pubitemid 29110752)
25. Burke MV, Ebbert JO, Hays JT. Treatment of tobacco dependence. Mayo Clin Proc 2008;83(4):479-83; quiz 83-84
26. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;1:CD000031 (Pubitemid 351820390)
27. Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol 2006;74(6):1153-1161 (Pubitemid 44950838)
28. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146 • Extensive review of nicotine replacement product efficacy.
29. Hughes JR, Shiffman S, Callas P, et al. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003;12(1):21-27 (Pubitemid 39456686)
30. West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berl) 2001;153(2):225-30 • NRT delivery preference study.
31. Tonnesen P, Norregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA. 1993;269(10):1268-1271 (Pubitemid 23067430)
32. Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J 1997;10(7):1585-1590 (Pubitemid 27311077)
33. Hurt RD, Dale LC, Croghan GA, et al. Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels. Mayo Clin Proc 1998;73(2):118-125 (Pubitemid 28099747)
34. Choi JH, Dresler CM, Norton MR, et al. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003;5(5):635-644 (Pubitemid 37304838)
35. Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002;162(11):1267-1276 (Pubitemid 34595033)
36. Ebbert JO, Sood A, Hays JT, et al. Treating tobacco dependence: review of the best and latest treatment options. J Thorac Oncol 2007;2(3):249-256 (Pubitemid 47181332)
37. Smith JW, Mogg A, TafiE, et al. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 2007;190(2):157-170 (Pubitemid 46011176)
38. Tutka P. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opin Investig Drugs 2008;17(10):1473-85 •• Extensive review of cytisine, the parent compound of varenicline.
39. Reavill C, Walther B, Stolerman IP, et al. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 1990;29(7):619-624 (Pubitemid 20225074)
40. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48(10):3474-7 •• Key paper on the discovery of varenicline.
41. Lesage MG, Shelley D, Ross JT, et al. Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav 2008 Sep 9. [Epub ahead of print]
42. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52(3):985-994 (Pubitemid 46227486)
43. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296(1):64-71
44. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):47-55 •• Phase III clinical trial establishing the efficacy of varenicline.
45. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):56-63 •• Phase III clinical trial establishing the efficacy of varenicline.
46. Williams KE, Reeves KR, Billing CB Jr, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23(4):793-801 (Pubitemid 46646499)
47. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166(15):1571-7 •• Phase II clinical trial establishing the efficacy of varenicline.
48. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropioncontrolled trial with 1-year follow-up. Arch Intern Med 2006;166(15):1561-8 •• Phase II clinical trial establishing the efficacy of varenicline.
49. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29(6):1027-39 •• Phase III clinical trial establishing the efficacy of varenicline.
50. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29(6):1040-56 •• Phase III clinical trial establishing the efficacy of varenicline. (Pubitemid 47198885)
51. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103(1):146-154 (Pubitemid 350233424)
52. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63(8):717-724
53. US Food and Drug Administration. Public Health Advisory: Important Information on Chantix (varenicline), 2008. Available from: http://www.fda.gov/ CDER/Drug/advisory/varenicline.htm
54. Datamonitor. Nicotine dependence: market potential, 2008 . Report No. DMHC2348. www.datamonitor.com
55. Niconovum. 2008. Available from: http://www.niconovum.se/
56. The Institute for Safe Medication Practices. Strong safety signal seen for new varenicline risks, 2008. Available from: http://www.ismp.org/docs/ vareniclinestudy.asp
57. Hays JT. The risk-benefit balance of varenicline for smoking cessation. J Thorac Oncol 2008;3(9):949-50
58. Hughes JR. Smoking and suicide: a brief overview. [Letter] Drug Alcohol Depend 2008
59. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164(8):1269 (Pubitemid 47292423)
60. Steensland P, Simms JA, Holgate J, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 2007;104(30):12518-12523 (Pubitemid 47206170)
61. Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008;3(6):e2547